Skip to main content

Table 3 Logistic regression results with prescriptions of anti-asthma medication as outcome

From: A longitudinal study of cannabis use increasing the use of asthma medication in young Norwegian adults

 

Reference (OR = 1)

Unadjusted

Model 1

Model 2

OR

95% CI

p

OR

95% CI

p

OR

95% CI

p

Female gender

Male

1.79

1.22–2.41

< 0.001

2.00

1.45–2.75

< 0.001

2.15

1.51–3.05

< 0.001

Age

Continuous

0.98

0.91–1.05

0.551

0.98

0.91–1.05

0.547

0.96

0.89–1.05

0.370

Education

Continuous

0.98

0.92–1.05

0.615

   

0.97

0.90–1.05

0.442

Body mass index

Continuous

1.01

0.98–1.05

0.423

   

1.04

1.00–1.08

0.050

Asthma at T1

No asthma

2.60

1.67–4.05

< 0.001

2.48

1.52–4.03

< 0.001

2.49

1.50–4.13

< 0.001

Allergies at T1

No allergies

1.58

1.15–2.17

0.005

1.38

0.98–1.95

0.067

1.51

1.05–2.17

0.025

Smoking at T4

Never smoked

         

 Smoked daily before, but not now

 

1.47

0.99–2.18

0.054

   

1.15

0.73–1.83

0.540

 Smokes sometimes, but not daily

 

1.01

0.61–1.66

0.976

   

0.88

0.51–1.56

0.678

 Smokes daily

 

1.73

1.23–2.42

0.002

   

1.20

0.78–1.85

0.414

Cannabis use at T4

Never used cannabis

         

 Used cannabis before, but not last year

 

0.83

0.57–1.22

0.342

0.85

0.57–1.27

0.423

0.82

0.53–1.28

0.378

 Used cannabis last year

 

1.65

1.14–2.41

0.009

2.05

1.38–3.05

< 0.001

1.71

1.06–2.77

0.028

  1. Note: OR = odds ratio; 95% CI = 95% confidence interval of OR
  2. Data on prescriptions are taken from the Norwegian Prescription Database and and explanatory variables are taken from the longitudinal Young in Norway Study. Model 1 includes adjustment for gender, age, self-reported asthma or allergies in addition to cannabis smoking. Model 2 includes additional adjustment for education, BMI and smoking